The FDA granted 510(k) clearance and a CLIA waiver to Diasorin’s Liaison Nes Group A streptococcus rapid molecular test, enabling outpatient and decentralized testing with results in roughly 15 minutes. The assay required less than one minute of hands-on time and uses reagents stored at room temperature. Diasorin said the Nes system is compact and cloud connected for real-time reporting and that the Group A strep test becomes the second assay on the platform after the respiratory panel’s earlier influenza A, influenza B, RSV, and COVID-19 clearances. Company representatives positioned the new test as part of efforts to expand the Nes menu for high-impact infectious diseases. At an investor day last month, Diasorin projected the Nes system could generate more than $150 million in U.S. revenue by 2030, while a gastrointestinal panel on Liaison Plex also received FDA clearance in May.